anticoagulant

Glowing puzzle piece fitting into puzzle
Biotech

CSL pays $117M for option on phase 3 blood clotting specialist

CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy VarmX in return for $117 million upfront.
Nick Paul Taylor Sep 16, 2025 4:31am
pass the torch deal sell buy acquisition

Novartis inks $925M Anthos takeover to rejoin clot-busting race

Feb 11, 2025 5:21am
Graphic of a drop of blood made up of small data points and nodes

Regeneron anticoagulant bests enoxaparin, matches Eliquis

Dec 19, 2024 8:50am
visual of red blood cells

Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial

Sep 18, 2023 6:00am
neural regeneration

BMS, J&J's secondary stroke med doesn't stick the landing

Aug 28, 2022 3:36am
Merck Co

Racing Bayer, Merck gets FDA fast-track tag for anticoagulant

Aug 23, 2022 8:40am